Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

Eybpoosh, Sana; Malaie, Mona Kiminezhad

doi:10.1155/2018/8698263

Cited by 2 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, since the patients were recruited from this centre, we conceive our samples to be fairly representative of Uruguayan HCV-infected population. Nevertheless, we share the idea proposed by the authors [1] that having nationwide surveys would provide larger samples to support our studies. However, it is worth mentioning that such an approach would be very difficult to carry out in our country given that our HCV infection prevalence among general population is currently unknown [12].…”

supporting

confidence: 88%

“…We are very grateful to Dr. Sana Eybpoosh and Dr. Mona Kiminezhad for their valuable comments and suggestions [1] on our recent article entitled “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients” [2].…”

mentioning

confidence: 99%

“…We have carefully reviewed all the comments [1] and hope that the provided responses will address the concerns on validity and generalizability of our results.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Response to: Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

et al. 2019

View full text Add to dashboard Cite

supporting

confidence: 88%

mentioning

confidence: 99%

See 1 more Smart Citation

Response to: Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

et al. 2019

View full text Add to dashboard Cite

Host Versus Virus: The Genetics in HCV Infection Leading to Treatment

Maqsood¹,

Hussain²,

Sumrin³

2023

Hepatitis C - Recent Advances

View full text Add to dashboard Cite

The spread of hepatitis C virus (HCV) infection is a worldwide crisis. Emerging evidence reveals the host-viral interactions govern the natural course and treatment response, individualy. For pegylated interferon plus ribavirin treatment, the response is most strongly predicted by the patient's HCV genotype. HCV genotype 1 with subtypes is the most important viral component in determining the success of direct-acting antiviral treatmenst. In addition to baseline viral load and HCV genomic heterogeneity, these two factors are linked with the treatment response. In chronic HCV infection, hosts’ genetic variations in immune responsive genes, have been identified as predictors of spontaneous disease progression and therapeutic outcome. In previous large genome-wide association studies, interferon3 gene polymorphisms have been shown to be linked with spontaneous clearance and treatment responsiveness. An inosine triphosphatase gene polymorphism has been shown to reduce the risk of anaemia and other side effects caused by the antiviral drug ribavirin. Hepatic steatosis and fibrosis are linked to a second genetic mutation in the patatin-like phospholipase domain containing 3 genes in HCV patients. This study examined the role of viral and host genetics in the natural history and treatment outcomes of HCV infection, and it is focused on the known viral and host variables linked with patient outcomes in HCV infection. This will result in fresh concepts of individualising, both the preventation to therapeutics.

show abstract

Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

Cited by 2 publications

References 11 publications

Response to: Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

Response to: Comment on “Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients”

Host Versus Virus: The Genetics in HCV Infection Leading to Treatment

Contact Info

Product

Resources

About